Most Popular Reagents
Instruments
Antibodies
ELISA Kits
Protein Electrophoresis and Blotting
Protein and Antibody Purification
Recombinant Proteins
Molecular Biology
Stable Cell Lines
Cell Isolation and Activation
IVD Raw Materials
Therapy Applications
Resources
| $211.00 | |
| A01931-40 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
| Specificity | The product is specific for Nivolumab. This antibody serves as an excellent positive control for Nivolumab immunogenicity (ADA) assays. |
| Host Species | Rabbit |
| Immunogen | Nivolumab |
| Conjugate | Unconjugated |
| Working concentrations for specific applications should be determined by the investigators. The appropriate concentration may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product. | |||||
|
|||||
| Form | Lyophilized |
| Storage Buffer | lyophilized with PBS, pH 7.4, containing 0.02% sodium azide. |
| Reconstitution | Reconstitute the lyophilized powder with deionized water (or equivalent) to an final concentration of 0.5 mg/mL. |
| Storage Instructions | The lyophilized product remains stable for 1 year at -20℃ from the date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8℃ or for 12 months at -20℃ or below. Avoid freeze/thaw cycles. |
| Purification | Antigen affinity purification |
| Isotype | Rabbit IgG |
| Clonality | Polyclonal |
| Clone ID | Not applicable |
| Note | GenScript can customize this product per customer's request including product size, buffer components, etc. |
»
ELISA binding of Anti-Nivolumab Antibody, pAb, Rabbit (GenScript, A01931-40) with Nivolumab.
Coating antigen: Nivolumab, 1 µg/ml.
Anti-Nivolumab Antibody, pAb, Rabbit (GenScript, A01931-40) dilution start from 1,000 ng/ml, EC₅₀= 12.42 ng/ml. »
| Target Background | Nivolumab (Opdivo) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma. Nivolumab binds to the human cell surface receptor PD-1 (Programmed Cell Death Protein 1) and blocks its interaction with PD-L1, resulting in the activation of T-cell-mediated immune responses against tumor cells. |
| Synonyms | Rabbit polyclonal to Opdivo |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
